論文 - 詳細
| RRC ID | 57784 |
|---|---|
| 著者 | Chowdhury MR, Moshikur RM, Wakabayashi R, Tahara Y, Kamiya N, Moniruzzaman M, Goto M. |
| タイトル | In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations. |
| ジャーナル | Int J Pharm |
| Abstract |
In order to prevent common hypersensitivity reactions to paclitaxel injections (Taxol), we previously reported an ionic liquid-mediated paclitaxel (IL-PTX) formulation with small particle size and narrow size distribution. The preliminary work showed high PTX solubility in the IL, and the formulation demonstrated similar antitumor activity to Taxol, while inducing a smaller hypersensitivity effect in in vitro cell experiments. In this study, the stability of the IL-PTX formulation was monitored by quantitative HPLC analysis, which showed that IL-PTX was more stable at 4 °C than at room temperature. The in vivo study showed that the IL-PTX formulation could be used in a therapeutic application as a biocompatible component of a drug delivery system. To assess the in-vivo biocompatibility, IL or IL-mediated formulations were administered intravenously by maintaining physiological buffered conditions (neutral pH and isotonic salt concentration). From in vivo pharmacokinetics data, the IL-PTX formulation was found to have a similar systemic circulation time and slower elimination rate compared to cremophor EL mediated paclitaxel (CrEL-PTX). Furthermore, in vivo antitumor and hypersensitivity experiments in C57BL/6 mice revealed that IL-PTX had similar antitumor activity to CrEL-PTX, but a significantly smaller hypersensitivity effect compared with CrEL-PTX. Therefore, the IL-mediated formulation has potential to be an effective and safe drug delivery system for PTX. |
| 巻・号 | 565 |
| ページ | 219-226 |
| 公開日 | 2019-6-30 |
| DOI | 10.1016/j.ijpharm.2019.05.020 |
| PII | S0378-5173(19)30373-4 |
| PMID | 31077761 |
| MeSH | Administration, Intravenous Animals Antineoplastic Agents, Phytogenic / administration & dosage* Antineoplastic Agents, Phytogenic / pharmacokinetics Cell Line, Tumor Drug Delivery Systems* Drug Hypersensitivity Female Glycerol / administration & dosage Glycerol / analogs & derivatives* Glycerol / pharmacokinetics Ionic Liquids / administration & dosage* Ionic Liquids / pharmacokinetics Melanoma / drug therapy Mice, Inbred C57BL Paclitaxel / administration & dosage* Paclitaxel / pharmacokinetics Skin Neoplasms / drug therapy |
| IF | 4.845 |
| 引用数 | 5 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | News |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | B16 F10(RCB2630) |